Aflibercept 8 mg Phase III Study Shows Vision Gains with Extended Treatment Intervals in Retinal Vein Occlusion
Bayer announced positive topline results from the global Phase III QUASAR study, which evaluated the efficacy and safety of aflibercept 8 mg in patients with macular edema following retinal vein…
EYLEA HD 8 mg Phase 3 Trial Shows Improved Vision with Extended Dosing in Macular Edema
Regeneron Pharmaceuticals, Inc announced today that the Phase 3 QUASAR trial investigating EYLEA HD® (aflibercept) Injection 8 mg has successfully met its primary endpoint. The trial evaluated the treatment of…
Lilly and EVA Pharma Announce Regulatory Approval and Launch of Locally Manufactured Insulin in Egypt
The Egyptian Drug Authority has granted regulatory approval for insulin glargine injection manufactured by EVA Pharma in collaboration with Eli Lilly and Company. This approval marks a significant milestone in…
Lilly’s Kisunla (donanemab-azbt) Approved in China for Early Alzheimer’s Treatment
Eli Lilly and Company announced today that China’s National Medical Products Administration (NMPA) has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Lilly’s Alzheimer’s treatment…
Merck Announces FDA BLA Acceptance for Clesrovimab to Protect Infants from RSV
Merck known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for clesrovimab (MK-1654),…
Duvakitug Phase 2b Results Highlight Potential in IBD Treatment
Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., have announced promising results from the RELIEVE UCCD phase 2b study, which met its primary endpoints in patients…
FDA Grants Breakthrough Status to Trodelvy for 2nd-Line ES-SCLC Treatment
Gilead Sciences, Inc announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for adult patients with extensive-stage small cell lung cancer…
Gilead & Terray Partner on Multi-Target Small Molecule Therapies
Gilead Sciences, Inc and Terray Therapeutics, Inc. have entered into a strategic collaboration aimed at discovering and developing novel small molecule therapies across multiple therapeutic targets. This partnership leverages Terray’s…
Merck Updates KeyVibe & KEYFORM Trials for Cancer Combos
Merck known as MSD outside of the United States and Canada, has announced the discontinuation of clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody. Vibostolimab…
ViiV: CHMP Backs Long-Acting HIV Treatment for Adolescents in Europe
GSK plc has announced that ViiV Healthcare, the global HIV-focused company majority owned by GSK with Pfizer and Shionogi as shareholders, received a positive opinion from the Committee for Medicinal…
Grifols Named Top Biotech Company in Dow Jones Sustainability Indices
Grifols, a global healthcare leader and prominent manufacturer of plasma-derived medicines, has achieved the distinction of being ranked the number one biotechnology company in the S&P Dow Jones Sustainability Indices…
ORCHESTRA Study Insights Guide Next Steps in UCB s Parkinson’s Research Program
UCB has announced results from the ORCHESTRA proof-of-concept study evaluating minzasolmin, an investigational oral small molecule developed in collaboration with Novartis to inhibit alpha-synuclein misfolding in early-stage Parkinson’s disease. Unfortunately,…